Research & Development

Automated Cell Therapy Enhanced by Cellares and Sony Collaboration
Research & Development Automated Cell Therapy Enhanced by Cellares and Sony Collaboration

The landscape of cell therapy manufacturing is on the brink of transformation as Cellares, an Integrated Development and Manufacturing Organization (IDMO), partners with Sony Corporation to integrate advanced cell analysis and sorting technologies into an already sophisticated manufacturing

DEA Delays Stall MMJ's Cannabis Trials for MS and Huntington's Disease
Research & Development DEA Delays Stall MMJ's Cannabis Trials for MS and Huntington's Disease

The ongoing legal battle between MMJ BioPharma Cultivation and the Drug Enforcement Administration (DEA) exemplifies the hurdles faced by companies attempting to break into pharmaceutical-grade cannabis research. MMJ BioPharma has encountered significant bureaucratic delays, stalling their efforts

Are New Cancer Treatments Bringing Hope to Patients with NSCLC?
Research & Development Are New Cancer Treatments Bringing Hope to Patients with NSCLC?

Recent advancements in cancer treatments have provided new hope for patients, with significant progress showcased in the biopharmaceutical industry. The interim results of ArriVent BioPharma, Inc.'s Phase 1b FURTHER trial for their drug firmonertinib have been particularly promising. This

How Will Cellares and Sony Transform Cell Therapy Manufacturing?
Research & Development How Will Cellares and Sony Transform Cell Therapy Manufacturing?

The world of cell therapy manufacturing is on the verge of a significant transformation. The partnership between Cellares, a leader in automated cell therapy manufacturing, and Sony Corporation, a technological giant renowned for its advanced flow cytometry, promises to reshape this burgeoning

Can Centessa's New Drug Revolutionize Sleep Disorder Treatments?
Research & Development Can Centessa's New Drug Revolutionize Sleep Disorder Treatments?

Sleep disorders are a growing public health concern, impacting millions of individuals worldwide. Addressing these disorders effectively has long been a challenge for pharmaceutical companies. Enter Centessa Pharmaceuticals, a London-based biotechnology company that has made headlines with its

Somite and OmniaBio Partner for AI-Driven DMD Cell Therapy Development
Research & Development Somite and OmniaBio Partner for AI-Driven DMD Cell Therapy Development

The recent partnership between Somite Therapeutics and OmniaBio Inc. marks a promising leap forward in treating Duchenne muscular dystrophy (DMD). Combining Somite's AI-driven approach with OmniaBio's cell and gene therapy expertise, this collaboration aims to expedite the development of

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later